aid: immunitas-therapeutics
name: Immunitas Therapeutics
description: >-
  Immunitas Therapeutics is a Boston, Massachusetts clinical-stage biotechnology company that
  discovers and develops novel antibody therapeutics for patients with cancer and autoimmune
  disease. It was founded by cancer-research and therapeutic-antibody scientists from Dana-Farber
  Cancer Institute, Mass General Cancer Center, the Broad Institute and MIT, whose single-cell
  analysis drug-discovery platform identified CD161 as a T-cell target. The lead program, IMT-009,
  is an anti-CD161 antibody in a Phase 1/2a study in solid tumors and hematological malignancies;
  a second, preclinical anti-CD161 program (IMT-380) for chronic inflammatory disease was licensed
  to Boehringer Ingelheim in May 2026. Immunitas publishes no public API, developer portal or
  machine-readable API contract. Its only public software is open source research tooling from the
  immunitastx GitHub organization, notably the MIT-licensed Python package monkeybread for
  analyzing cellular niches in single-cell spatial transcriptomics data.
image: https://static1.squarespace.com/static/6164da62fcac550608373bab/t/6182f75661dfa17d0caa4ec2/1635972950201/immunitas_logo.png?format=1500w
url: https://raw.githubusercontent.com/api-evangelist/immunitas-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Therapeutics
- Oncology
- Immunology
- Autoimmune Disease
- Single-Cell Analysis
- Spatial Transcriptomics
- Bioinformatics
- Open Source
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.immunitastx.com/
- type: PrivacyPolicy
  url: https://www.immunitastx.com/privacy-policy
- type: TermsOfService
  url: https://www.immunitastx.com/terms-and-conditions
- type: Support
  url: https://www.immunitastx.com/home#contact
- type: GitHubOrganization
  url: https://github.com/immunitastx
- type: LinkedIn
  url: https://www.linkedin.com/company/immunitas/
- type: GitHubRepository
  url: https://github.com/immunitastx/monkeybread
- type: Packages
  url: packages/immunitas-therapeutics-packages.yml
- type: DomainSecurity
  url: security/immunitas-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/immunitas-therapeutics-llms.txt
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 4
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Immunitas Therapeutics is a clinical-stage antibody drug developer (IMT-009, anti-CD161) whose
    entire public web presence is a four-page Squarespace marketing site — its own sitemap.xml
    lists only /home, /privacy-policy, /terms-and-conditions and /rdday, with no developer, docs or
    API page anywhere — so the only machine-readable software it publishes is the MIT-licensed
    monkeybread Python package for spatial-transcriptomics analysis, which calls no Immunitas
    service.
  evidence:
  - url: https://www.immunitastx.com/sitemap.xml
    status: 200
  - url: https://www.immunitastx.com/openapi.json
    status: 404
  - url: https://www.immunitastx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.immunitastx.com/llms.txt
    status: 404
  - url: https://pypi.org/pypi/monkeybread/json
    status: 200
  checked: '2026-08-23'